These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 20014977)

  • 1. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future.
    Jacob N; Stohl W
    Autoimmunity; 2010 Feb; 43(1):84-97. PubMed ID: 20014977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunological basis of B-cell therapy in systemic lupus erythematosus.
    Mok MY
    Int J Rheum Dis; 2010 Feb; 13(1):3-11. PubMed ID: 20374380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.
    Moulton VR; Suarez-Fueyo A; Meidan E; Li H; Mizui M; Tsokos GC
    Trends Mol Med; 2017 Jul; 23(7):615-635. PubMed ID: 28623084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BCMA and autoantibody-producing RP105 B cells; possible new targets of B cell therapy in systemic lupus erythematosus].
    Koarada S; Tashiro S; Suematsu R; Inoue H; Ohta A; Tada Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):38-45. PubMed ID: 22374441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
    Pan Q; Xiao H; Shi L; He Y; Cai J; Wu J; Li A; Ye L; Yang C; Liu HF
    Front Immunol; 2020; 11():1047. PubMed ID: 32625200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell biology: implications for treatment of systemic lupus erythematosus.
    Anolik JH
    Lupus; 2013 Apr; 22(4):342-9. PubMed ID: 23553777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR.
    Fu SM; Deshmukh US; Gaskin F
    J Autoimmun; 2011 Sep; 37(2):104-12. PubMed ID: 21632208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selfie: Autoimmunity, boon or bane.
    Ahsan H
    J Immunoassay Immunochem; 2017; 38(3):235-246. PubMed ID: 28421864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus.
    De Groof A; Hémon P; Mignen O; Pers JO; Wakeland EK; Renaudineau Y; Lauwerys BR
    Clin Rev Allergy Immunol; 2017 Oct; 53(2):181-197. PubMed ID: 28500565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of an anti-RNA autoantibody in a mouse model of SLE increases neutrophil and monocyte numbers as well as IFN-I expression.
    Han JH; Umiker BR; Kazimirova AA; Fray M; Korgaonkar P; Selsing E; Imanishi-Kari T
    Eur J Immunol; 2014 Jan; 44(1):215-26. PubMed ID: 24105635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do naturally occurring autoantibodies participate in the constitution of the pathological B-cell repertoire in systemic lupus erythematosus?
    Gilbert D; Brard F; Jovelin F; Tron F
    J Autoimmun; 1996 Apr; 9(2):247-57. PubMed ID: 8738970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis.
    Blanco P; Ueno H; Schmitt N
    Eur J Immunol; 2016 Feb; 46(2):281-90. PubMed ID: 26614103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
    Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
    Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target.
    Lou H; Ling GS; Cao X
    J Autoimmun; 2022 Oct; 132():102861. PubMed ID: 35872103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B and T cell tolerance and autoimmunity in autoantibody transgenic mice.
    Yan J; Mamula MJ
    Int Immunol; 2002 Aug; 14(8):963-71. PubMed ID: 12147633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibody repertoire analysis in normal and lupus-prone mice.
    Starobinski M; Lacour M; Reininger L; Izui S
    J Autoimmun; 1989 Oct; 2(5):657-74. PubMed ID: 2803476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor signalling in B cells during systemic lupus erythematosus.
    Fillatreau S; Manfroi B; Dörner T
    Nat Rev Rheumatol; 2021 Feb; 17(2):98-108. PubMed ID: 33339987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.
    Moulton VR; Tsokos GC
    J Clin Invest; 2015 Jun; 125(6):2220-7. PubMed ID: 25961450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.